Oppenheimer set a $15.00 target price on Intec Pharma (NASDAQ:NTEC) in a research report released on Thursday, November 16th. The brokerage currently has a buy rating on the biotechnology company’s stock.
A number of other equities analysts have also issued reports on the company. Zacks Investment Research upgraded Intec Pharma from a sell rating to a hold rating in a research note on Wednesday, October 11th. CIBC reiterated an outperform rating and set a $15.00 price objective (up previously from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. Finally, Roth Capital set a $10.00 target price on Intec Pharma and gave the company a buy rating in a research report on Thursday, August 10th. One investment analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and a consensus target price of $11.00.
Shares of Intec Pharma (NTEC) traded down $0.15 during mid-day trading on Thursday, reaching $5.55. The company had a trading volume of 91,737 shares, compared to its average volume of 44,903. Intec Pharma has a one year low of $4.20 and a one year high of $9.80.
A number of hedge funds have recently bought and sold shares of NTEC. Migdal Insurance & Financial Holdings Ltd. boosted its holdings in Intec Pharma by 5.0% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock worth $2,977,000 after buying an additional 25,000 shares during the last quarter. Caxton Corp acquired a new position in shares of Intec Pharma during the 3rd quarter worth approximately $681,000. Sectoral Asset Management Inc acquired a new position in shares of Intec Pharma during the 3rd quarter worth approximately $3,177,000. Finally, Pura Vida Investments LLC acquired a new position in shares of Intec Pharma during the 3rd quarter worth approximately $895,000. Institutional investors own 40.16% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Intec Pharma (NTEC) PT Set at $15.00 by Oppenheimer” was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another domain, it was stolen and republished in violation of US & international copyright law. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/04/oppenheimer-holdings-inc-analysts-give-intec-pharma-ltd-ntec-a-15-00-price-target.html.
About Intec Pharma
Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.
Receive News & Ratings for Intec Pharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.